Physician

Bushra Javed, M.D

According to 2025 Medicare claims, Bushra Javed, M.D (NPI: 1629322987) practices neurology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is RALEIGH NEUROLOGY ASSOCIATES, P. A. (NPI: 1215954003; TIN: 562002729) and primary practice location at 27607-5253. Javed is affiliated with the HSHS ACO, L.L.C. (ACO ID: A2783), participating under the MSSP model.

Javed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 350 traditional Medicare patients, billed 20,383 HCPCS/CPT codes, and received $501,259 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,701 prescription claims across 319 beneficiaries totaling $263,916 in drug costs, led by Gamunex-C (Immune Globul G/Gly/Iga Avg 46). 2017 DME data shows 22 claims. Open Payments data shows 169 records totaling $3,740. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $14,398 and ending at $501,259. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	107	164	$14,398
2017	472	2,745	$78,610
2018	395	5,702	$90,886
2019	482	7,214	$132,671
2020	394	5,491	$99,679
2021	336	9,049	$149,561
2022	71	393	$12,461
2023	165	3,971	$98,012
2024	350	20,383	$501,259

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	12	46	$3,372
2016	24	51	$1,436
2017	146	630	$36,051
2018	221	1,323	$452,644
2019	349	1,879	$765,459
2020	375	2,055	$744,157
2021	388	2,310	$976,876
2022	261	1,248	$528,918
2023	155	564	$507,504
2024	319	1,701	$263,916

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	22	$246
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	98	98	$145
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	32	32	$129
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	117	146	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	111	130	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	221	325	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	12	336	$85,044
Aimovig Autoinjector	Erenumab-Aooe	14	522	$13,104
Entacapone	Entacapone	17	1,285	$5,658
Memantine Hcl	Memantine Hcl	156	8,259	$3,191
Rivastigmine	Rivastigmine	13	810	$2,914

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	169	$3,740	Alexion Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bushra Javed, M.D?

Tedicare shows public-source Medicare data for Bushra Javed, M.D (NPI 1629322987), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bushra Javed, M.D have ACO affiliation data?

Bushra Javed, M.D is shown with ACO affiliation data for HSHS ACO, L.L.C. (MSSP, ACO ID A2783).

What billing organization is linked to Bushra Javed, M.D?

Bushra Javed, M.D is linked to RALEIGH NEUROLOGY ASSOCIATES, P. A. (billing NPI 1215954003) in the available physician profile data.

Does Bushra Javed, M.D have Open Payments data?

Bushra Javed, M.D has 169 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.